Pall Biotech has announced a new end-to-end integrated platform solution that accelerates development, reduces risk and simplifies your process for gene therapy manufacturing.

The company provides a fully integrated, scalable, and single-use gene therapy solution from development through to commercialisation, from upstream and downstream processing through to formulation and filling.

Key features include:

  • Simplify and streamline your process while reducing the risk for operator error
  • Reduce time-to-market
  • Reduce overall cost of goods

A presentation explaining this feature is available. Depending on your preference, Pall Biotech can arrange for an on-site visit by one of its technical specialists or a presentation can be delivered via webex.

Contact the company using the enquiry form for more information.